Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Cross Above 200 Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $49.71 and traded as high as $66.06. Global X Genomics & Biotechnology ETF shares last traded at $65.13, with a volume of 41,272 shares.

Global X Genomics & Biotechnology ETF Price Performance

The firm has a market cap of $97.76 million, a price-to-earnings ratio of -28.62 and a beta of 1.17. The firm’s fifty day moving average is $56.98 and its 200-day moving average is $49.86.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently declared a dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 29th were paid a $0.0579 dividend. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is -27.35%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A number of institutional investors and hedge funds have recently made changes to their positions in GNOM. Bank of America Corp DE increased its stake in Global X Genomics & Biotechnology ETF by 67.8% in the 1st quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after acquiring an additional 48,394 shares during the last quarter. Sei Investments Co. boosted its position in Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after buying an additional 12,105 shares during the period. Jane Street Group LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after buying an additional 10,308 shares during the last quarter. Wealth Management Partners LLC purchased a new position in Global X Genomics & Biotechnology ETF during the 1st quarter valued at $244,000. Finally, Smartleaf Asset Management LLC lifted its position in shares of Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares during the period. Institutional investors and hedge funds own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.